Physician profile
Robert G Aptekar
NPI 1811982259
$1,072.14
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $124 · 2021: $386 · 2022: $84.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $263.24 | 2020-2021 | |
| Nuvasive, INC. | $125.00 | 2021 | |
| Osiris Therapeutics INC. | $123.29 | 2019 | |
| Heron Therapeutics, INC. | $121.84 | 2021 | |
| Smith+Nephew, INC. | $120.83 | 2019 | |
| Medtronic USA, INC. | $106.56 | 2019 | |
| Medtronic, INC. | $84.54 | 2022 | |
| Endo Pharmaceuticals INC. | $56.43 | 2019 | |
| Electronic Waveform Lab, INC. | $36.35 | 2019 | |
| Bioventus LLC | $22.26 | 2019 | |
| Avanos Medical | $11.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Aptekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.